How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration (FDA) was established to assess the potential impact of nanotechnology on drug products. One of the working group's major initiatives has been to conduct a comprehensive risk management exercise regarding the potential impact of nanomaterial pharmaceutical ingredients and excipients on drug product quality, safety, and efficacy. This exercise concluded that current review practices and regulatory guidance are capable of detecting and managing the potential risks to quality, safety, and efficacy when a drug product incorporates a nanomaterial. However, three risk management areas were identified for continued focus during the review of drug products containing nanomaterials: (1) the understanding of how to perform the characterization of nanomaterial properties and the analytical methods used for this characterization, (2) the adequacy of in vitro tests to evaluate drug product performance for drug products containing nanomaterials, and (3) the understanding of properties arising from nanomaterials that may result in different toxicity and biodistribution profiles for drug products containing nanomaterials. CDER continues to actively track the incorporation of nanomaterials in drug products and the methodologies used to characterize them, in order to continuously improve the readiness of our science- and risk-based review…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“That is, there is not a distinct or definitive set of critical quality attributes (CQAs), which can accurately predict the in vivo similarity of two distinct nano-based pharmaceuticals or biologic products.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [288]
In the citing paper
“Thus, a wide variety of evidence is needed to show equivalence which includes long term clinical monitoring and extensive PK data [288, 293–295].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [288]
In the citing paper
“Encapsulation in nanoparticles changes the size, surface properties, and other characteristics which affect in vivo drug behavior when compared to traditional formulations composed of low molecular weight API and excipients.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [288]
In the citing paper
“Regulatory appraisal has to deal with its impact on safety and efficacy profiles. This calls for increased scrutiny and rigor in the review process [288, 291, 292].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [288]
In the citing paper
“Unlike in traditional drug formulations, similar physicochemical properties of nano-based pharmaceuticals are not often a predictor of similar in vivo behavior [288, 293, 295]”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [288]
Citations
Cites
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Self-citationSadrieh, N., Wokovich, A. M., Gopee, N. V., Zheng, J., Haines, D., Parmiter, D., Siitonen, P. H., Cozart, C. R., Patri, A. K., McNeil, S. E., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq041 · Cited by 309
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 289
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene
Zhang, C., Tang, N., Liu, X., Liang, W., Xu, W., & Torchilin, V. P. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.022 · Cited by 210
Properties of the Log-Normal Particle Size Distribution
Heintzenberg, J. (1994) · Aerosol Science and Technology · doi:10.1080/02786829408959695 · Cited by 195
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
Li, M., Zou, P., Tyner, K., & Lee, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0010-3 · Cited by 165
Self-citation
Research works printed but not linked: 2
- Christopher R Beekman, MM., Adil Mohammad, Adarsh Gandhi, Dajun Sun, Wenlei Jiang, Robert Lionberger, Rodney Rouse, Vikram Patel., Determining the bio-distribution of colloidal iron drug products in rats by inductively coupled plasma mass spectrometry (ICP-MS). NYAS workshop, Equivalence of complex drug products: Scientific and regulatory challenges (Nov 9, 2016) 2016.
- Wu M, Sun D, Tyner K, Jiang W, Rouse R. Comparative in vitro cellular uptake study on reference and generic sodium ferric gluconate in mononuclear phagocyte systems. 2016 NYAS Workshop, Equivalence of complex drug products; Scientific and Regulatory challenges (Nov 9, 2016) 2016.
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications
Mohammadpour, R., Dobrovolskaia, M. A., Cheney, D. L., Greish, K. F., & Ghandehari, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.006 · Cited by 280
Organ-specific toxicity of magnetic iron oxide-based nanoparticles
Chrishtop, V. V., Mironov, V. A., Prilepskii, A. Y., Nikonorova, V. G., & Vinogradov, V. V. (2021) · Nanotoxicology · doi:10.1080/17435390.2020.1842934 · Cited by 86
Improving Biopharmaceutical Safety Through Verification‐Based Quality Control
Yu, Y. B., Taraban, M. B., Wang, W., & Briggs, K. T. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.08.010 · Cited by 23
Metadata
- Authors
- Tyner, K. M., Zheng, N., Choi, S., Xu, X., Zou, P., Jiang, W., Guo, C., & Cruz, C. N.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Cruz, Celia N.
- ORCID
- Venue
- The AAPS Journal
- Published
- 2017-04-18
- Volume
- 19
- Issue
- 4
- Pages
- 1071-1083
- ISSN
- 1550-7416 (ISSN-L)
- OpenAlex
- W2607360117
- Cited by
- 33
- References
- 49
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 3 · 2017: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The AAPS Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › General Materials Science › Nanotechnology research and applications
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- nanotechnology, risk management, nanomaterial characterization, nanomaterial toxicity, tissue distribution, regulatory guidelines, regulatory research, FDA Center for Drug Evaluation and Research
- MeSH terms
- United States, United States Food and Drug Administration, Drug Approval, Risk Assessment, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. https://app.cochat.ai/papers/10.1208/s12248-017-0084-6
- The paper
- Tyner, K. M., Zheng, N., Choi, S., Xu, X., Zou, P., Jiang, W., Guo, C., & Cruz, C. N. (2017). How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. The AAPS Journal. https://doi.org/10.1208/s12248-017-0084-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.